Deeply rooted in Science
Our deep scientific expertise is rooted in decades of immunological research by Prof. Dr. Dolores J. Schendel and her team.
living
immunotherapies
We are empowering T cells to effectively fight cancer.
Immunotherapies show great promise to revolutionize cancer treatment. Therefore, we put living T cells - key players in the immune system - at the center of our technology platforms. We are striving to create breakthrough therapies to fundamentally improve the lives of cancer patients.
Latest News
Positive final 2-year topline data in completed DC vaccine Phase I/II trial in AML patients
Interim 1-year clinical immune monitoring data from DC vaccine trial in AML presented at ASH 2019 Annual Meeting
Fighting cancer with cutting-edge technologies
The therapeutic potential of human T cells can radically change the future of cancer treatment. Medigene uses its proprietary platform technologies to modify T cells for the fight against tumor cells, thereby activating the body’s own immune defense mechanisms. Our focus is on the development of tumor-specific T cells (TCR-Ts).
TCR-Ts
Our focus: Generating large numbers of cancer-specific T cells to recognize and kill cancer cells.
Capacity to innovate
The cumulated scientific knowledge and experience of our scientists, allied with high-throughput automation technologies, accelerate the discovery and development process for new therapies.
Growing pipeline
Our first TCR-T therapy MDG1011 has entered clinical development, augmenting the proprietary clinical-stage DC vaccines. We aim to fill our immunotherpy pipeline of with more natural TCR-Ts and prepare them for clinical development.
Nimble and efficient
At Medigene, we combine state-of-the-art science and an entrepreneurial start-up culture within the structures of an established biopharmaceutical company.
MORE ABOUT OUR COMPANY
MDG 1
Listed at Frankfurt Stock Exchange, WKN: A1X3W0
> 100
Headquarter in Martinsried near Munich and a US-Office in San Diego, USA, approximately 140 employees
+32 %
Revenue from the core business of immunotherapies increased to €6,2 m (9M-2018: €4,7 m) mainly driven by the partnerships with bluebird bio and Roivant/Cytovant
Partner-like
Medigene has developed several clinical stage drugs, ranging from the research phase to commercialization and product launch onto the market. In cooperation with partners, we intend to become a global leader in the field of T cell immunotherapies.
"We look forward to generating clinical data in cell therapy programs and to further developing our technologies with the goal to ultimately make next-generation immunotherapies for hematological cancers and solid tumors a reality for patients and physicians"
Dolores Schendel, CEO
Living immunotherapies, together
Our highly qualified scientists are dedicated to working at the forefront of cancer immunotherapies. Working closely with our experienced business specialists, they jointly develop highly innovative and effective therapies in order to help patients with severe illnesses.